

DOI: 10.5152/imj.2018.45712

Makale türü: Orijinal Investigation

Türkçe Başlık: Potansiyel İlaç Etkileşimlerinin Önlenmesinde Serbest Eczanelerde Kullanılan Bilgisayarlı İlaç Etkileşimi Kontrol Programlarının Önemi: Klaritromisin ile Yapılan Bir Ön Çalışma

Türkçe Kısa Başlık: İlaç etkileşimi kontrol programları

İngilizce Başlık: The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin

İngilizce Kısa Başlık: Drug interaction checker programs

Yazarlar: Abdullah Şimşek¹, Çağlar Macit², Neda Taner¹, Barkın Berk³, Güldem Mercanoğlu⁴

Kurumlar:

¹Department of Clinical Pharmacy, İstanbul Medipol University School of Pharmacy, İstanbul, Turkey

²Department of Pharmacology, İstanbul Medipol University School of Pharmacy, İstanbul, Turkey

³Department of Pharmaceutical Chemistry, İstanbul Medipol University School of Pharmacy, İstanbul, Turkey

⁴Department of Pharmacology, University of Health Sciences School of Pharmacy, İstanbul, Turkey

Corresponding Author/ Sorumlu Yazar: Güldem Mercanoğlu

E-mail: guldemiko@gmail.com, habibegulden.mercanoglu@sbu.edu.tr

Received/Geliş Tarihi: 01.08.2018

Accepted/Kabul Tarihi: 21.09.2018

Cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

Abstract/Öz

Introduction: Drug-drug interactions (DDI) due to multiple drug use are the most important cause of adverse drug reactions (ADR). DDIs are among medication errors that can be prevented. Computerized drug interaction checker programs are important tools to reduce possible DDIs (PDDI) as it is no longer practical for physicians to rely on memory alone to avoid potential drug interactions. The aim of this study is to investigate the role of computerized drug interaction checker programs in the identification and prevention of PDDIs in clarithromycin prescribed pediatric outpatients.

Methods: The study was a retrospective observational prescription analysis held in three community pharmacies operating in the province of Uskudar-Istanbul during 12-month period. The prescriptions with oral clarithromycin medication were selected and PDDIs were analyzed using the RxMediaPharma® software on an active substance base.

Results: During the 12-month period, 100 prescriptions containing 266 medicines prescribed by 52 different physicians were collected. The average number of medicines per prescription was 2.66 ± 1.11 . Of the 16 PDDIs detected, 5 were clarithromycin (31.25%) and 11 were non-clarithromycin (68.75%). When PDDIs were categorized by severity, 10 out of 16 (62.5%) were major, 2 (12.5%) were moderate and 4 (25%) were minor. Clarithromycin interactions were moderate with lidocaine and minor with both metronidazole and sultamycin (ampicillin / sulbactam).

Conclusion: Although evidence based computerized drug interaction checker programs that provide rapid access is not sufficient alone, they can help health care professionals for preventing the PDDIs. The use of this program in the community pharmacies could minimize PDDIs during the dispensing of medicine.

Keywords: Drug interactions, computerized drug interaction checker program, adverse drug reactions

Amaç: Çoklu ilaç kullanımına bağlı olarak gelişen ilaç-ilaç etkileşimleri (DDI) advers ilaç reaksiyonlarının (ADR) en önemli nedenidir. İlaç hatalarından bir tanesi olarak sayılan DDI önlenmelidir. Sağlık profesyonellerinin tıbbi ve pratik bilgilerinin yanında kullanacakları entegre bilgisayarlı ilaç etkileşimi kontrol sistemleri, tek başlarına yeterli olmamakla beraber olası etkileşimlerin azaltılması için sağlık personeline yardımcı olabilir. Bu çalışmada ayaktan pediatri hastalarına reçete edilen klaritromisin ile potansiyel DDI'ların (PDDI) belirlenmesi ve önlenmesinde bilgisayarlı ilaç etkileşimi kontrol sistemlerinin rolünün araştırılması amaçlanmıştır.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

Yöntemler: Retrospektif gözlemsel reçete analizi niteliğinde olan bu çalışmada, 12 aylık periyotta (Ocak-Aralık 2016) pediatrik ayaktan hastalara solunum yolu enfeksiyonu tanısı ile oral klaritromisin yazılan reçeteler İstanbul ili Üsküdar ilçesinde faaliyet gösteren ve çalışmaya katılmayı kabul eden, üç serbest eczaneden toplanarak müstahzar isim ve sayıları ile hasta demografik verileri (yaş, cinsiyet) kayıt edildi. PDDI'ler etkin madde bazında RxMediaPharma® programı ile tespit analiz edildi.

Bulgular: On iki aylık periyotta 52 farklı hekim tarafından 266 adet müstahzarın reçetelendiği 100 adet reçete toplanmış olup, reçete başına ortalama müstahzar sayısı 2.66 ± 1.11 idi. Tespit edilen 16 PDDI'nın 5'i klaritromisin (%31.25) ve 11 tanesi klaritromisin dışı (%68.75) idi. PDDI'ler şiddet bazında kategorize edildiğinde, toplam 16 etkileşimden 10 tanesi (%62.5) yüksek, 2 tanesi (%12.5) orta ve 4'ü (%25) düşük idi. Klaritromisin etkileşimleri ise: lidokain ile orta; metronidazol ve sultamisin (ampisilin/sulbaktam) ile ise minör kategorisinde idi.

Sonuç: Hızlı erişim imkânı sağlayan bilgisayarlı ilaç etkileşimi kontrol sistemleri tek başlarına yeterli olmamakla beraber PDDI'lerin önlenmesinde sağlık personeline yardımcı olabilir. Bu sistemlerin serbest eczanelerde kullanımı ilacın hastaya verilmesi esnasında yaşanacak olan DDI'ların önlenmesinde oldukça önem taşımaktadır.

Anahtar Kelimeler: ilaç etkileşimi, bilgisayarlı ilaç etkileşimi kontrol programı, advers ilaç reaksiyonları

Introduction

Although there is no definite consensus on its definition, polypharmacy is basically defined as the use of multiple drugs at the same time for more than one indication (1). The main problem with multi-drug use is drug-drug interactions (DDI). DDI can be described as a change in the effect of a drug when used in combination with another drug. DDI may cause an increase or decrease both in the effectiveness and efficacy of the drugs used together, or it may lead to the development of adverse drug reactions (ADR) (2). Studies show that DDIs account for 3 to 5% of treatment errors in the hospitals. ADR developed as a result of DDI have been reported as the main cause of around 10-20% of hospitalizations (3), and 4 to 6 of the causes of death in hospitalized patients (4). It is, therefore, important to prevent harmful potential DDIs (PDDI) to prevent drug-related morbidity and mortality and to ensure drug safety during outpatient treatment.

Among drug medications, DDIs can easily be prevented (5). However, each year, a large number of medicines are offered to the market, and as a result, interactions between medicines are gradually increasing. For this reason, it is no longer practical for physicians to trust only to their memory in the prevention of PDDIs (6). Additionally, especially due to

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

huge number of patients visiting the primary health care facilities, limited examination time is allocated to each patient and consequently the physicians are not adequately informed about the medication used by the patients. Thus, this leads to duplicated prescriptions and DDIs (7). To prevent this, there are certain computerized drug interaction checker programs, however, these are not sufficient alone since they can aid health professionals to reduce potential interactions only if they are integrated into the medical and practical knowledge of health professionals (6).

Although the importance of increase in ADR risk caused by pediatric polypharmacy induced PDDI, as in adult patients, is widely accepted, research in this area is quite rare. The information obtained from such research will help physicians develop drug use habits for pediatric patients and will enable the design of safer systems for drug prescription ordering or subsequent drug follow-up (8, 9).

Non-steroidal anti-inflammatory drugs and antibiotics are the most frequently prescribed drug groups in primary care practices (6). Clarithromycin, a member of macrolide group, is a widely preferred antibiotic in the treatment of respiratory tract infections in children with a broad spectrum of antimicrobial activity, a relatively low rate of adverse events, and ease of dosing twice daily (10).

The aim of this study is to investigate the role of computerized drug interaction checker programs in the identification and prevention of PDDIs in clarithromycin prescribed pediatric outpatients.

Materials and Methods

This study was a retrospective observational prescription analysis held in Uskudar-Istanbul for a period of 12-month from January to December 2016. Paediatric outpatient clarithromycin prescriptions with a diagnosis of respiratory tract infection were collected from three different community pharmacies located around three different family medicine clinics.

The prescriptions were analysed with respect to the medicine (name and number) and the patient demographic data (gender and age). The active ingredients of the prescribed medicines were determined and PDDIs were checked via RxMediaPharma® database (11). For medicines containing more than one active substance (for example combined cold medications), the analysis was performed for each active substance. The severity of PDDIs was classified according to Table 1 by the software program.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

The local ethical committee approval was obtained for the study (İstanbul Medipol University Ethical Committee for Non-Interventional Clinical Investigations, dated: 18.01.2017, number: 01). Informed consent was not obtained in this study.

Statistical Analysis

Data were analyzed descriptively and presented as frequencies and percentages using SPSS version 21.

Results

A total of 100 prescriptions were examined and 51 of the prescriptions were written for 0-2 years, 48 for 2-6 years and 1 for 6-18 years of age. The distribution of prescriptions by age and gender is shown in Table 2.

In a total of 100 prescriptions 266 different medicines were found to be written by 52 different physicians. The average number of medicines per prescription was 2.66 ± 1.11 . In 44 of the prescriptions there were more than 3 medicines prescribed (Figure 1). The number of prescription-based medicines was higher in the 0-2 age groups. From the prescriptions examined a total of 16 PDDIs were identified, 5 of which were clarithromycin (31.25%) and 11 of them were non-clarithromycin (68.75%). Of the PDDIs identified, 72.3% were in the same prescription and 27.7% were in different prescriptions. The active substances that were found to interact with clarithromycin in the RxMediaPharma® program were lidocaine, metronidazole and sultamicillin. Of the total 5 prescriptions, 3 were lidocaine and 1 was metronidazole and sultamicillin (Table 3).

When PDDIs were examined on a severity basis, 10 out of 16 (62.5%) were high, 2 (12.5%) were moderate and 4 (25%) were low. DDIs with clarithromycin were moderate with lidocaine; low with metranidazole and sultamicillin (ampicillin/sulbactam) (Table 4).

Discussion

Drug interactions in multidrug use are a potential concern. Although comprehensive drug evaluations are effective, they are very labor intensive and costly. It is possible to avoid interaction and dose-related errors with integrated drug systems that health professionals use in conjunction with medical and practical information.

This study investigated the efficacy of drug interaction checker programs in the prevention of PDDI with pediatric prescribing clarithromycin. This group of patients was chosen for several reasons. First of all, this group of patients is more susceptible to medication errors. Additionally, the medical management of the pediatric patients presents unique challenges throughout the medication use process. Furthermore, studies with this group of patients are few in number (12). Macrolide group antibiotics is the most commonly prescribed group

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

after penicillin in pediatric patients, and clarithromycin, one of the group members, is the most frequently prescribed active substance after erythromycin (13). DDI induced Q-T prolongation with clarithromycin is the major concern despite the relatively low rate of adverse events (10). Although variety of checker programs exist for the evaluation of PDDIs (Micromedex, Lexicomp, Medscape, Rx MediaPharm etc), owing to the price advantage, RxMediaPharm is the most widely preferred program in the community pharmacies.

In this study, of the detected 16 PDDIs, 5 were clarithromycin (31.25%) and 11 were non-clarithromycin (68.75%). In the literature the PDDI ratio reported widely ranges between 19% and 90% (14-16). This broad difference in range reported by various studies might be due to the difficulties in conducting standardized prevalence studies in the area (17). The 16% rate reported in this study can be explained by the fact that the prescriptions were collected from a limited number of pharmacies that were relatively close in locations.

Studies show that PDDI rates vary depending on the healthcare centres that the patients refer to. While in emergency services PDDI rate is 16% in outpatients, it is 70% in family medicine policlinics (18). Unlike previous study, however, the PDDI rate was found to be 16% in the present study. We should note here that although the prescriptions were collected from pharmacies located around the family medicine policlinics, they were collected only from three community pharmacies.

It is known that DDIs are proportional to the number of medicine used concomitantly. Karas and colleagues reported that while the estimated prevalence of PDDI in patients using two different medicines was 5.6%, the ratio was 56% in five different medicine users and 100% in seven different medicine users (19). Similarly, Goldberg and colleagues reported the prevalence of PDDI to be 13% for two medications and 80% for seven and above drug use (20). We also found that 72.3% of the interactions in our study were of the same prescription and that the incidence of PDDI increased with the increase in the amount of medicines written per prescription. Among the prescriptions collected, there were more prescriptions for 0-2 age group patients, and the number of medicines per prescription was high. We think that physicians tended to prescribe more medicines to this age group since the patients in this age group are unable to express themselves parents are more prone to direct the physicians in assessing the symptoms.

In our study, the majority of detected PDDIs (n=10, 62.5%) were in high-risk category. It should be emphasized once again that the findings we obtained identify only PDDIs, because the database used in our study was insufficient to determine the clinical ADR (21). Similar previous studies showed that despite the high prevalence of PDDI, the PDDI prevalence that may cause clinically significant ADRs is low (22). According to Peng and colleagues, among the 2% PDDIs identified by sophisticated DDI checker program, only 0.04% of the total

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

prescriptions were clinically relevant DDI which was identified by the combination of DDI checker program and clinical pharmacist review (23). On the other hand, it should be noted that ADRs may result in significant morbidity and mortality, and that the level of evidence for the severity of 62% of PDDIs is based on clinical practice (24,25).

It is noteworthy that three of the five-clarithromycin interactions detected in our study were with lidocaine prescribed by different physicians. Both pharmacokinetics and pharmacodynamics interaction are seen with lidocaine. When given in combination with lidocaine, clarithromycin causes an increase the risk of ventricular arrhythmia by QT prolongation, on the other hand enhances the lidocaine effect / level by inhibiting the CYP3A4 enzyme (26). For this reason, during treatment patients should be monitored with ECG and motorization of serum lidocaine levels is suggested.

In our study, although the clarithromycin-to-metronidazole interaction was indicated as a low risk by the checker program, there are a few studies suggesting the prolongation of QT interval by metronidazole (27). Theoretically, co-administration of medications that can prolong QT interval may lead to an increased risk of ventricular arrhythmia, including torsade de pointes and sudden death. Although QT prolongation and ventricular arrhythmia were reported in patients treated with metronidazole in isolated studies, a causal relationship has not been established due to underlying conditions involved and concomitant medications in these studies (27).

The interaction with clarithromycin and sultamicillin (ampicillin / sulbactam) was also classified as "low" in our study. Although some in-vitro data indicate synergism between macrolides and penicillins, some in-vitro studies showing antagonism also exist. Although data is available for erythromycin, theoretically this interaction may occur with other macrolides. According to the literature, there is no need to take any special precaution other than monitoring the effectiveness of treatment for this interaction (28-30).

Surveys show that 39% of medical errors occur during the prescribing process and 11% during the dispensing process (31). Tightening the control steps can significantly reduce DDIs and ARDs, important part of drug errors experienced during the prescribing procedure. Two important tools developed for this purpose are hospital information system and e-order system (32). With these systems, the physician can observe PDDIs and ADRs during prescribing procedure (33,34). Still the main problem with these systems is that patients do not always take their medical care from the same healthcare providers (35). Especially in the Eastern cultures, it is common for patients to visit multiple hospitals with the same or similar conditions, to change their doctors and/or hospitals (36,37). There are studies showing that patients who receive medical care from different healthcare providers are more likely to suffer ADRs (36,38). These systems are often designed for use in a single hospital or one

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

managed care organization settings, and they do not have a common infrastructure for sharing the patient's medication history (34). For this reason, PDDI controls with these systems cannot go beyond hospital boundaries (39). Even though the computerized drug support and drug interaction checker programmes have been developed to close this gap, the main issue with these programmes is that they are stand-alone programs, which cannot be integrated into patient management systems. Therefore, for each check, physician should transfer data from the patient management system into DDI database and repeat this process for each prescribed medicine (34). Especially in healthcare facilities with huge volume of outpatients, limited examination times of physicians is the biggest obstacle for the effective use of these programs. Consequently, prior to the initiation of treatment the pharmacist, as the last ring of the healthcare chain in contact with the patient, is the final line of defense against harmful PDDIs (7).

Routine use of drug interaction checker programs in community pharmacies, which provide fast access, can help pharmacist for the prevention of vital malfunctions such as PDDIs. The usage of these programs in combination with the medical and practical knowledge of health professionals could increase the quality and ensure the safety of the healthcare services offered.

Conclusion

Computerized drug interaction checker programs with rapid access are not sufficient alone, but can help health professionals to prevent of PDDIs. The use of these programs, especially in community pharmacies, can serve for the identification of DDIs during delivery of the medicine to the patient. To ensure the effective use of the programs by health professionals, they need to be standardized to provide clinically relevant ADRs in line with evidence based information, along with their integration into e-order systems. Hence, DDIs and ADRs caused by DDI during both prescribing and dispensing will be prevented more effectively.

Study limitation: The basic limitation we should note here is that the prescriptions were collected from a limited number of community pharmacies. Despite the fact that 12 pharmacies were invited to take part in the study, 6 pharmacies indicating the workload did not agree to participate. What is more, during data collection process 3 pharmacies that did not regularly provide prescriptions were excluded from the study. Therefore, a generalizability of the findings may be a limiting factor.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

References

1. Wyles H, Rehman HU. Inappropriate polypharmacy in the elderly. *Eur J Intern Med* 2005; 16: 311-313. <https://doi.org/10.1016/j.ejim.2005.02.006>
2. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *The Lancet* 2000; 356 1255-1259. [https://doi.org/10.1016/S0140-6736\(00\)-02799-9](https://doi.org/10.1016/S0140-6736(00)02799-9).
3. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ* 2004; 329:15-19. <https://doi.org/10.1136/bmj.329.7456.15>.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 1998; 279: 1200-1205. <https://doi.org/10.1001/jama.279.15.1200>.
5. Dirim MM, Mousavi S, Tabrizian K, Afshari A, Ashrafi MH. Potential drug-drug interactions in prescriptions dispensed in community and hospital pharmacies in East of Iran. *J Res Pharm Pract* 2014; 3:104-107. <https://doi.org/10.4103/2279-042X.141118>.
6. Ansari J. Drug Interaction and Pharmacist. *J Young Pharm* 2010; 2: 326-331. <https://doi.org/10.4103/0975-1483.66807>.
7. Abarca J, Malone D, Skrepnek G, Rehfeld R, Murphy J, Grizzle AJ et al. Community pharmacy managers' perception of computerized drug-drug interaction alerts. *J Am Pharm Assoc* 2003; 46: 148-153. <https://doi.org/10.1331/154434506776180676>.
8. Aagaard L, Christensen A, Hansen EH. Information about adverse drug reactions reported in children: a qualitative review of empirical studies. *Br J Clin Pharmacol* 2010; 70:481-491. <https://doi.org/10.1111/j.1365-2125.2010.03682.x>.
9. Harper MB, Longhurst CA, McGuire TL, Tarrago R, Patterson A. Core Drug-drug interaction alerts for inclusion in pediatric electronic health records with computerized prescriber order entry. *J Patient Saf* 2014; 10: 59-63. <https://doi.org/10.1097/PTS.000000000000050>.
10. King SM. Claritromycin for children. *Can J Infect Dis* 1995; 6:69-70.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

11. GEMAŞ A.Ş., RxMediaPharma® İnteraktif İlaç Bilgi Kaynağı, <https://www.eczanet.com/rxmediapharma> (accessed January 1, 2017).
12. Benavides S, Huynh D, Brias L. Approach to the pediatric prescription in a community pharmacy. *J Pediatr Pharmacol Ther* 2011; 16:298-307. <https://doi.org/10.5863/1551-6776-16.4.298>.
13. Clavenna A, Bonatti M. Differences in antibiotic prescribing in pediatric outpatients. *Arch Disease Child* 2011; 96: 590-595. <https://doi.org/10.1136/adc.2010.183541>.
14. Reimche L, Forster AJ, van Walraven C. Incidence and contributors to potential drug-drug interactions in hospitalized patients. *J Clin Pharmacol* 2011; 51:1043-1050. <https://doi.org/10.1177/0091270010378858>.
15. Straubhaar B, Krahenbuhl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. *Drug Saf* 2006; 29: 79-90.
16. Kliegman B, Nelson J. *Textbook of Pediatrics*, 17th ed., Elsevier, Philadelphia, USA, 2003.
17. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. *JAMA* 1986; 256: 3358-3363.
18. Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbafe S, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. *Journal Pain Symptom Manage* 2008; 35: 535-543. <https://doi.org/10.1016/j.jpainsymman.2007.06.009>.
19. Karas S, Jr. The potential for drug interactions. *Ann Emerg Med* 1981; 10: 627-630.
20. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. *Am J Emerg Med* 1996; 14: 447-450.
21. Sarrazin MS, Rosenthal GE. Finding pure and simple truths with administrative data. *JAMA* 2012; 307: 1433-1435. <https://doi.org/10.1001/jama.2012.404>.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

22. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. *Expert Opin Drug Saf* 2012; 11: 83-94. <https://doi.org/10.1517/14740338.2012.631910>.
23. Peng CC, Glassman PA, Marks IR, Fowler C, Castiglione B, Good CB. Retrospective drug utilization review: Incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. *J Manag Care Pharm* 2003; 9:513–522. <https://doi.org/10.18553/jmcp.2003.9.6.513>.
24. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, et al. Concordance of severity ratings provided in four-drug interaction compendia. *J Am Pharm Assoc* 2004; 44: 136–141.
25. Fulda TR, Valuck RJ, Zanden JV, Parker S, Byrns PJ. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. *Curr Ther Res* 2000; 61:540-48
26. Aritmal Ampul Kısa Ürün Bilgisi (KUB) <http://www.titck.gov.tr/KubKt/Index> (accessed April 18, 2018).
27. Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. *Pacing Clin Electrophysiol* 2005; 28: 472-473.
28. Strom J. Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them. *Antibiot Chemother* 1961; 11: 694-697.
29. Cohn JR, Jungkind DL, Baker JS. In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens. *Antimicrob Agents Chemother* 1980; 18: 872-876.
30. Penn RL, Ward TT, Steigbigel RT. Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes. *Antimicrob Agents Chemother* 1982; 22: 289-294.
31. Holdsworth, MT, Fichtl RE, Raisch DW, Hewryk A, Behta M, Mendez ER, et.al. Impacts of computerized prescribe order entry on the incidence of adverse drug events in pediatric patients. *Pediatrics* 2007; 120: 1058-1066.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

32. Fiumara K, Moniz T, Churchill WW. Case Study on the use of health care technology to improve medication safety In: Porché RA (Ed). Medication Use: A Systems Approach to Reducing Errors. Joint Commission Resources, USA, 2008, pp 103-114,
33. Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM. Effect of computerized provider order entry and a team ^[L]_[SEP]intervention on prevention of serious medication errors. JAMA 1998; 280: 1311-1316. ^[L]_[SEP]
34. Kuperman GJ, Bobb A, Payne TH, Avery AJ, Gandhi TK, Burns G, et al. Medication-related clinical decision support in computerized provider order entry ^[L]_[SEP]systems: A review. J Am Med Inform Assoc 2007; 14: 29-40. ^[L]_[SEP]
35. Yeh YT, Hsu MH, Chen CY, Lo YS, Liu CT. Detection of potential drug-drug interactions for outpatients across hospitals. Int J Environ Res Public Health 2014; 11: 1369-1383. <https://doi.org/10.3390/ijerph110201369>.
36. Chen TJ, Chou LF, Hwang SJ. Patterns of ambulatory care utilization in Taiwan. BMC Health Serv Res 2006; 6:54–61. <https://doi.org/10.1186/1472-6963-6-54>.
37. Sato T, Takeichi M, Hara T, Koizumi S. Second opinion behaviour among Japanese primary care patients. Br J Gen Pract 1999; 49:546–550. ^[L]_[SEP]
38. Donkor ES, Quarcoo TPB, Nartey P, Agyeman IO. Self-Medication practices with antibiotics among tertiary level students in Accra, Ghana: A cross-sectional study. Int. J. Environ. Res. Public Health 2012; 9: 3519–3529. ^[L]_[SEP] <https://doi.org/10.3390/ijerph9103519>.
39. Hsu MH, Yeh YT, Chen CY, Liu CH, Liu CT. Online detection of potential duplicate medications and changes of physician behavior for outpatients visiting multiple hospitals using ^[L]_[SEP]national health insurance smart cards in Taiwan. Int J Med Inform 2011; 80: 181-189. <https://doi.org/10.1016/ijmedinf.2010.11.003>. erph110201369.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712

Table 1. Classification of interaction by R_x Media Pharma® Program

Severity	Explanation
High	The interaction between these drugs can be life threatening or cause permanently damage. These drugs are not usually used together, they require medical intervention. An alternative medicine should be used.
Moderate	The clinical impact of interaction is limited, but can be disturbing. Patient should be monitored for the findings of interaction.
Low	Interaction may occur depending on the mechanism of action of co-administered drugs. Caution should be taken with regard to the reduced or increased efficacy related to the combined drugs.

Table 2. Distribution of prescriptions by age and gender

Age	Number of Prescription (n, %)		
	Female	Male	Total
0-2	23 (45.1)	28 (54.9)	51
3-6	17 (35.4)	31 (64.6)	48
7-18	0 (0.0)	1 (100.0)	1

Table 3. Classification of interaction with clarithromycin by R_x Media Pharma®

Active Substance	Number of Prescription	Severity	Possible Result
Lidocaine	3	High	Prolongation of QT interval, Myocardial depression
Metronidazole	1	Low	Risk on the prolongation of QT interval
Sultamicillin	1	Low	Risk on reduction in pharmacological effect.

Table 4. Distribution of PDDIs according to the severity

Severity	Age			Total
	0-2	3-6	7-18	
Low	2	2	0	4
Moderate	2	0	0	2
High	6	4	0	10
Total	10	6	0	16

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712




Figure 1. Distribution of medicines per prescription

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to

differences between this version and the Version of Record. Please cite this article as: Şimşek A, Macit Ç, Taner N, Berk B, Mercanoğlu G. The Importance of Computerized Drug Interaction Checker Programs to Avoid Potential Drug-Drug Interactions used in Community Pharmacies: A Preliminary Study with Clarithromycin. DOI: 10.5152/imj.2018.45712